Home Depot's CEO says the retailer cut its outlook partly due to "the potential impacts to the U.S. consumer arising from recently announced tariffs."Retailread more
For investors still haunted by last week's monster sell-off, the market's comeback is set to last, according to J.P. Morgan's quant guru.Marketsread more
A U.S.-China trade deal would be less likely if President Xi cracks down violently on the large-scale protests in Hong Kong, Secretary of State Mike Pompeo tells CNBC.Politicsread more
The launch follows a "preview" earlier this month that allowed only limited customers to apply.Technologyread more
Financial advisers are always "buying at the wrong time and selling at the wrong time because they're emotional," the billionaire founder of Baron Capital says.Marketsread more
Energy stocks may be fueling up for a comeback rally. One technical analyst says that after the sector's pummeling, these two stocks look particularly good.Trading Nationread more
Bruce Linton says he bought more stock in Canopy Growth — even though the cannabis company he co-founded fired him earlier this summer.Health and Scienceread more
A new probe could bring more pressure to some of the nation's largest tech firms, which are already facing scrutiny on the federal level.Technologyread more
Got extra stuff? Got extra space? A new company is ready to make a match. Neighbor is a barely two-year-old company that connects homeowners online with people who need...Real Estateread more
The company confirmed it's hiring a team of veteran journalists to help curate news stories in its soon-to-launch news tab.Technologyread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
* Q1 sales up 8 pct to 14.8 bln francs vs f'cast 14.2 bln
* Drug sales up 10 pct to 11.9 bln francs vs f'cast 11.2 bln
* Sees mid single-digit revenue growth in 2019 (Adds comments from drugs division chief, CEO, analysts)
ZURICH, April 17 (Reuters) - Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald Trump's pressure on the industry to hold down charges.
Roche, the world's biggest cancer drug maker, now sees mid single-digit revenue growth, up from the previous forecast of low- to mid-single digit growth. It sees core earnings per share mirroring sales growth.
Drugs division chief Bill Anderson said Roche's drug revenue is soaring even as it honors a price-freeze pledge it made last year after Trump took to the phone and Twitter to urge companies to back off price hikes.
"We haven't taken any price increases in the U.S. since July 1," Anderson said on a call. "Overall in the world, our 10 percent sales growth in pharma was based on 15 percent volume growth and 5 percent average price declines across the portfolio."
Chief Executive Severin Schwan is getting a lift as sales of newer drugs offset erosion of older cancer drugs that face fierce competition in Europe.
Multiple sclerosis drug Ocrevus's sales rose by two-thirds to 836 million francs, while cancer immunotherapy Tecentriq jumped two-fold to 336 million. Breast cancer medicine Perjeta rose 41 percent to 870 million francs and Hemlibra, Roche's new hemophilia A drug, hit 219 million francs.
"I'm very pleased that 90 percent, the vast majority of our growth, comes from our new medicines," Schwan said.
Still, a big unknown for the Austrian CEO is how swiftly rivals' soon-to-be-launched copies of Roche's $22 billion-per-year cancer medicines Rituxan, Herceptin and Avastin will eat into U.S. sales this year and next.
"Roche can keep up the unbroken growth, as long as Ocrevus, Hemlibra and the entire (breast cancer) franchise maintain their momentum," Zuercher Kantonalbank analyst Michael Nawrath said.
Schwan expects the $4.3 billion takeover of Philadelphia-based Spark Therapeutics to be completed by June, despite a regulatory hiccup with the U.S. Federal Trade Commission that required an extension.
"Our firm expectation is it will close at the conditions we have offered," the CEO said.
First-quarter sales rose 8 percent to 14.8 billion Swiss francs ($14.7 billion), beating the 14.2 billion Infront Data poll average estimate. Drug sales rose 10 percent to 11.9 billion francs, besting the 11.2 billion poll average, while diagnostics sales edged higher.
Roche shares were little changed at 269 francs by 0800 GMT, beating a 1.5 percent drop in the STOXX Europe 600 Health Care Index.
($1 = 1.0069 Swiss francs) (Reporting by John Miller Editing by Michael Shields and David Holmes)